Correction: *On the mechanism of anti-CD39 immune checkpoint therapy*

Allard D, Allard B, Stagg J. On the mechanism of anti-CD39 immune checkpoint therapy. *J Immunother Cancer* 2020;8:e000186. doi: 10.1136/jitc-2019-000186

In this article, there was an error in the formatting of the P2X receptors in the text. This error has since been corrected.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

J Immunother Cancer 2020;8:e000186corr1. doi:10.1136/jitc-2019-000186corr1